Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Stock Information for Boundless Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Boundless Bio Inc.

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.